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We examined the effect of methySphenidate (Mph) on inhibition and several other
cofiuitive iihililie.s in 43 adults with Attention Deficit Hyperactivity Disorder (ADHD)
hy use of Conners' Continuous Performance Test (CPT) and the Change Task (ChT).
an e.\ten.sion of the Stop Si}>nal Test fSST). In a double blind, cross-over, placebo
controlled study wifh Mph. te.sts were administered during the third week of individu-
ally titrated treatment with Mph {maximum dose I mg / k^ / day) and during the third
week of treatment with placebo. We established large medication effects for commis-
sion errors, standard error of mean reaction time, and attentiveness on the CPT. as
well as moderate medication effects for mean reaction lime on lhe CPT and response
re-engagement speed on the ChT. For Slop Signal Reaction Time (SSRT) <m the ChT,
we also estahlished large effects of Mph. hut only in a group of participants who
.showed slow SSRTs on placebo. Mph indeed ameliorates inhibition, which is the core
problem of ADHD, and certain other cognitive abilities in adulls with ADHD.
Introduction
For decades. Attention Deficit Hyperactivity Disorder (ADHD) has been thought to affect
only children. In the last 15 years or so, however, researchers have established that children
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do not always outgrow their problems with attention, hyperactivity. and impulsivity once
they reach adulthood. Rather, between 30 to .'iO'^  of children with ADHD still meet the
requirements for the diagnosis in adulthood (Biedennan. Mick, & Faraone, 2(KM): Manuzza.
Klein, Bessler. Malloy, & LaPadula, 1998; Weiss. Hechtman. Mi!roy. & Periman. 1985).
This has lead to prevalence estimates tor the United States of 1-6% of the general popula-
tion (Wender. Wolf. & Wasserstein. 2001). Epidemiologic studies have confirmed these
figures in adults applying for a driver's license (Murphy & Barkley. 1996) and in college
students (Heiligenstein. Conyers, Bems, Miller, & Smith. 1998).
For a long time, attention problems and hyperactivity have been the most researched
symptoms of this disorder, but recently impulsivity is increasingly seen as the symptom of
greatest significance (Taylor, 1998). According to several theories, impulsivity or decreased
inhibition of behavior even is the central impairment of ADHD (Barkley, 1997; Nigg, 2(K)I;
Pennington & Ozonoff. 1996; Schachar. Tannock. & Logan, 1993). A possible explanation
for this shift may be found in the current thought that inhibitory control plays an important
role in attentional systems, which makes the inattention in ADHD a secondary symptom.
As Rubia, Oosterlaan. Sergeant. Brandeis and van Leeuwen (1998) stated: "For example,
failure to sustain attention may be due to failure to inhibit interfering activities and distract-
ibility may be caused by not inhibiting attention to irrelevant information" (p. 25). The
extensive empirical evidenee for deficits in inhibition in children with ADHD is derived
from studies using different inhibition paradigms, for instance the Stop Signal Test (SST).
In a meta analysis on SST data in ADHD children. Oosterlaan, Logan, and Sergeant (1998)
demonstrated that children with ADHD exhibit significantly slower response inhibition
times than normal control children. This finding was confirmed in a more reeent review of
SST studies in children (Sergeant, Geurts, & Oosterlaan. 2tK)2). Another paradigm that has
often been employed in successfully establishing inhibition deficits in children with ADHD
is the Continuous Performance Test (CPT) (Brandeis et al., 1998; Kerns. Mclnemey, &
Wilde, 2001). For reviews of CPT studies in children with ADHD, see Corkum and Siegel
(1993), Losier, McGrath, and Klein (1996), and Riccio, Waldrop, Reynolds, and Lowe
(2001). Deficits in inhibition have also been established for adults with ADHD, using both
the SST (Epstein, Johnson. Indira, & Conners, 2001; Murphy, 2002; Ossmann & Mulligan,
2003; Wodushek & Neuman, 2(X)3), and the CPT (Barkley. Grodzinsky. & DuPauI, 1992;
Epstein. Conners. Sitarenios, & Erhardt. 1998; Epstein et al.. 2001; Ossmann & Mulligan.
2003; Riccio & Reynolds. 2001; Walker, Shores, Trollor, Lee, & Sachdev, 2000).
The stimulant methylphenidate (Mph) is one of the most effective and safe medications
for the treatment of ADHD in children. Approximately 70% of ADHD children show a
therapeutic response to stimulant medication (Schachter, Pham, King. Langford, & Moher,
2(K)1; Wilens & Spencer, 2(XK)). In adults with ADHD, stimulant medication has received
far less attention than in children. In a recent review. (Wilens. Spencer, & Biederman, 2002)
seven Mph studies were mentioned, in which the weighted mean clinical response to
Mph treatment was 56%. In a recent meta anaiysis, Faraone, Spencer, Aleardi, Pagano. and
Biederman (2004) mentioned a mean effect size of 0.9 for six double-blind placebo-
controlled Mph treatment studies In adults with ADHD.
Mph has been shown to Improve inhibition on several laboratory tasks in children
with ADHD, such as the CPT (for a review see Losier et al., 1996). and the SST ( Scheres
et al.. 2003; Tannock. Schachar, Carr, Chajczyk, & Logan, 1989; Tannock, Schachar &
Logan, 1995). Information on the effect of Mph on inhibition and other cognitive variables
tested by the CPT in an adult ADHD population is limited. Riordan et al. (1999) established
a decrease in visual distractibility with Mph on a CPT. Kuperman et al. (2001) mentioned
improvement with Mph on attentiveness (one of the signal detection parameters) on a CPT
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in adults with ADHD, but no other parameters were reported. In the only study mention-
ing an effect of Mph on the inhibition parameter of a CPT, the effect was not significant
(Gualtieri. Ondrusek. & Finley, 1985). The effect of Mph on the Change Task (ChT,
which is an extended version of the SST) in an adult ADHD sample has not been reported
thus far. Given the current emphasis on inhibition in ADHD, this shortage of studies into
the effect of Mph on inhibition in adult ADHD is surprising. This is why in the present
study, we hypothesized that Mph would improve inhibition in adults with ADHD, both on
the CPT and the ChT. conipared to placebo.
In addition to inhibition, the CPT and the ChT measure several other variables of
cognitive functioning. The CPT provides information on processes related to response
execution (speed and variability), as well as measures that are related to signal detection
theory (perceptual sensitivity in discriminating targets from non-targets and response
style). Another interesting feature of the CPT is that stimuli may he presented with different
event rates, for instance I. 2 or 4 s between stimuli. This allows for analysis of the
involvement of behavioral activation in response execution. An optimal behavioral activa-
tion state influences motor adjustment, thus affecting response execution (Sanders. 1998).
The influence of activation level has been repeatedly indicated in ADHD in children
(Scheres, Oosterlaan. & Sergeant. 2001; Sergeant. 2000; Van der Meere. 1996).
The ChT provides information on similar response execution processes as the CPT.
Moreover, by instructing subjects to perform another action after they have inhibited their
prepotent response, it also supplies information on response re-engagement processes.
Performance on many of these variables has been shown to differ between children with
ADHD and normal controls (see Losier et al.. 1996: Oosterlaan et al.. 1998. Riccio et al.
2001). Similar information on adults with ADHD is sparse, but available studies indicate
that they also may show difficulties on some of the abilities mentioned above, such as
speed of response execution, and attentiveness (Epstein et al.. 1998; Epstein et al.. 2001).
Besides its positive eftect on the clinical symptoms of ADHD and on inhibition, stimulant
medication seems to improve specific other cognitive abilities. In children, it has been shown
to enhance response speed and accuracy (Klorman et al. 1988; Reid & Borkowski. 1984).
response variability {Tannock ct al.. 1995). and response re-engagement (Bamctt et al.. 2001;
Bernian. Douglas. & Barr. 1999; Kempton et al.. 1999; Solanto, 1997; Tannock et al.. 1995).
Studies with Mph in adults with ADHD have suggested that the drug may also improve
specific cognitive abilities in this group. Kupeniian et al. (2(H)!) showed advanced response re-
engagement abilities and increased fluency with Mph. Other researchers have found evidence
of increase in working memory ability (Kinsboume. De Quiros, & Tocci Rufo. 2(X)I). motor
speed, and processing speed, as well as decreases in distractibility (Riordan et al.. 1999).
Our first hypothesis stated that Mph would improve inhibition in adults with ADHD,
both on the CPT and the ChT. compared to placeho. In order to extend the knowledge of
the effect of Mph on cognitive abilities, other than inhibition, in adult ADHD, we further
hypothesized that several cognitive processes (speed of response execution, variability of
response execution, response re-engagement, attentiveness) measured by the CPT and the
ChT would improve with Mph, conipared to placebo.
Method
Participants
Forty-three adults with ADHD between 20 and 55 years of age (M = 38.9 years; SD= 10.1),
21 men and 22 women, participated in this study. Two of these participants were diagnosed
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with ADHD hyperactive / impulsive subtype, the other 41 were diagnosed with ADHD
combined subtype. None of the participants had been treated with Mph prior to this study.
The average IQ was 100.3 {SD 17.9; minimum 76, maximum 142). The participants
were either self-referred or referred by other clinicians lor assessment of ADHD to an
outpatient clinic in the Netherlands. Prior to inclusion in the study, participants underwent
a standardized clinical assessment consisting of a psychiatric evaluation by one of two
experienced psychiatrists. The following instruments were used: a semi-structured clinical
diagnostic interview for ADHD and comorbid disorders; several sections from the Dutch
version of the Diagnostic Interview Schedule (Robins et al.. 1995): section L (for the
retrospective diagnosis of ADHD in childhood), section N (for the retrospective diagnosis
of opposltional defiant disorder), section O (for the retrospective diagnosis of conduct
disorder), and section P (lor current antisocial personality disorder); the Dutch version of
the Composite International Diagnostic Interview (CIDI) (version 2.1, lifetime; Robins
et al.. 1988) for Axis I psychiatric disorders; the Dutch version of the International Person-
ality Disorder Examination (IPDE) (Loranger, Sartorius. Andreoli. & Berger. 1994) for
borderline and antisocial personality disorders. For current ADHD-symptoms during the
last 6 months, we used the Dutch version of the ADHD-Rating Scale (DuPauI. Power,
Anastopoulos. & Reid. 1998). based on the 18 DSM-IV symptom criteria tor ADHD. The
level of associated impairinent was assessed using the Dutch version of the Sheehan Dis-
ability Scale (SDS) (Sheehan, Hamett-Sheehan, & Rai, 1996) and the Global A.ssessment
of Functioning Scale (GAF) (APA, 1994). A medical hi.story, a physical examination
(blood pressure, pulse and weight), and laboratory assessments (complete blood cell
count, liver, kidney, thyroid, glucose function tests, and electrocardiogram) were also
obtained.
To be given a diagnosis of adult ADHD, subjects had to (I) currently meet at least
5 of 9 DSM-IV criteria of inattention and / or at least 5 of 9 DSM-IV criteria of hyperac-
tivity / impulsivity (based on the ADHD Rating Scale), (2) meet at least 6 of 9 DSM-IV
criteria of inattention and / or at least 6 of 9 DSM-IV criteria of hyperactivity / impulsivity
in childhood (based on the DIS- .section L). (3) describe a chronic persisting course of
ADHD symptoms from childhood to adulthood, and (4) endorse a moderate to severe
level of impairment attributed to ADHD symptoms. The cutoff point of 5 of 9 hyperactive /
impulsive symptoms and / or 5 of 9 inattention symptoms for adult diagnosis ot ADHD is
in line with previous research (Biederman et al.. 2000; Murphy & Barkley. 1996). In order
to obtain information about lifetime ADHD symptoms and impairment, the participant,
the partner (if available), and (if possible) the parents were interviewed. Information on
school reports was examined in order to substantiate the diagnosis in childhood. We esti-
mated the IQ of participants based on four subtests of the Dutch version of the Wechsler
Adult Intelligence Scale-Ill: Vocabulary. Arithmetic, Block Design, and Picture Arrange-
ment. The reliability of this short form has not been established for the WAIS-III yet, hut
for the WAIS-R these four tests have been found to estimate Full Scale IQ with greater
accuracy than other variations (Boone, 1990). Data for several diagnostic measures are
provided in Table 1.
Subjects with comorbid psychiatric disorders were Included, unless these disorders
required to be treated first (for instance severe depression or anxiety) or when treatment
with Mph was contra-indicated (for instance with hypertension). The number of eligible
participants was 108. Before study entry, 15 people withdrew consent for the trial. We
excluded 41 participants: lour with clinically significant medical conditions, one with
abnormal baseline laboratory values, seven with other psychiatric conditions that required
to be treated first, 11 because of current use of psyehotropics, and 18 because of prior use
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Table 1
Group Characteristics on Diagnostic Measures
Measure value M (SD)
Number of currently endorsed DSM-IV criteria for ADHD 15.5 (2.1)
Number of DSM-IV criteria for ADHD endorsed in childhood (DIS-L) 12.0 (4.1)
Sheehan Disability Scale (minimum 0, maximum 30) 22.8 (3.3)
Global Assessment of Functioning (minimum 0, maximum 100)' 57.3 (6.1)
Axis I CO morbid disorders (CIDI Lifetime)
• any co morbid disorder 79%
• multiple CO morbid disorders ( > 2) 53%
• any anxiety disorder 51%
• any mood disorder 53%
Axis II CO morbid disorders
• Antisocial Personality Disorder (IPDE) 9.3%
• Borderline Personality Di.sorder (IPDE) 16.3%
Note. CIDI = Composite International Diagnostic Interview; IPDE = International Personality
Disorder Examination.
'Scores above 70 indicate normal functioning.
of Mph or amphetamines. Other exclusion criteria were: a history of tic disorders, IQ
below 75, any neurological condition that could interfere with a diagnosis of ADHD (such
as concussion, meningitis, traumatic brain injury), suicidal behavior, psychosis, mania,
physical aggression, and pregnancy or nursing. No participants had to be excluded based
on these criteria. After study entry and full diagnostic assessment, seven participants were
ineligible: five due to current substance abuse, one due to hypertension, and one due to
severe depression that urgently required treatment. In the end, 45 participants were random-
ized and completed the trial. Data of two participants could not be used for the neuropsy-
chological part of the study due to incompletion (« - I) and positive urine screening for
opiates (n = 1). The study was approved by the local Medical Ethical Committee, and all
subjects completed a written informed consent form before inclusion in the study.
Materials
Continuous Performance Test. Computerized CPTs are often used to study vigilance in
ADHD populations. Most CPTs require a subject to press a key in response to a target
stimulus (for instance the letter X, or the letter A followed by an X) and to ignore non-
target stimuli. The version used in this study is the Conners' Continuous Pertbrmance Test
(Conners, 1995), which differs from traditional (X and A-X) CPT paradigms (Rosvold,
Mirsky, Sarason, Bransome. & Beck, 1956). In Conners' CPT, the response required for
the critical signal of X is to withhold a discrete and repetitive motor response, rather than
to respond to it. For all other stimuli, a response of pressing the space bar is required. This
means that omission errors indicate a failure to execute the required response, whereas
commission errors suggest an inability to inhibit the prepotent response. Next to sustained
attention, the main measurement objective of traditional CPTs, the Conners' CPT may
invoke executive or controlled attention (Ballard, 2001). As far as we know, this version
of the test has only been used in one study with Mph in an adult ADHD population
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(Kuperman et al., 2(H)1). However, this study only reported medication effects on the
dependent variable attentiveness (d').
The task consisted of six blocks of 60 trials. Each block contained three sub-blocks of
20 trials each. Stimuli presented were letters of approximately I inch in size. Ten percent
of stimuli in each block were Xs, with a total of 36 Xs for the entire test. Other letters
presented were A. B, C, D, E, F, H, I. L. M. N. O, T, Y, and Z. For each block, the sub-
blocks had different inter-stimulus intervals (ISIs): I, 2, or 4 s. The order of sub-blocks
randomly varied between blocks. Each letter was displayed for 250 ms. The most often
reported (and therefore also chosen for this study) dependent variables are: I) the number
of commission errors, measuring inhibitive behavior (high error rates indicate poor inhibitive
control), 2) mean reaction time for hits (to measure the latency of the response execution pro-
cess), 3) the standard error of the mean hit reaction time (an indication of the consistency
with which respondents can focus their attention), 4) attentiveness (d'), which is an indica-
tion of the ability to discriminate between targets and non-targets, and 5) risk taking (P)
(an indication of a person's response style: high values point to cautious response styles,
whereas low values suggest more risk taking). Omission errors were not analyzed for this
study, since the participants made hardly any errors of this type {M (placebo) = 2.4;
M(Mph)= 1.8).
Change Task. The Change Task (ChT) (Logan & Burkell. 1986) is an extension of the
Stop Signal Test (SST) (Logan, Cowan, & Davis, 1984). The SST measures response
execution and response inhibition processes, while the extended ChT is also used to inves-
tigate response re-engagement. To our knowledge, this test has not been used previously
in any studies with adults with ADHD.
The ChT used in this study consisted of go trials and stop trials. For hoth types of
trials, an airplane was presented for 1000 ms at either the left or the right side of the
screen. Immediately before stimulus onset, a fixation point (500 ms in duration) appeared
at the center of the screen. A right sided stimulus required subjects to press the right
response button as quickly as possible. If the airplane was presented on the left, the left
response button had to be pressed. Subjects were instructed to use the index and middle
fingers of their dominant hand. Between trials the screen turned blank for 15(X) ms. Stop
trials were identical to go trials, but in addition a stop signal (a 1000 Hz tone. 50 ms in
duration) was presented through stereo earphones. When a stop signal was presented,
participants were to withhold their response (i.e.. not to press any button with their domi-
nant hand). In addition, they had to press a different button with their nondominant thumb as
quickly as possible. This is the Change Response, a measure of response re-engagement.
Seventy-five percent of trials were go-trials, and 25% were stop trials. Trials were pre-
sented in blocks of 64 trials. Stop signals were presented at predetermined intervals before
the subject's expected response. This provides the opportunity to ascertain the ability to
inhibit a response at different points in the response execution process. The shorter the
time interval between the stop signal and the expected response, the more difficult it
becomes to inhibit this response. Intervals between stop signal and expected response
were set at 50 ms, 200 ms, 350 ms. or 500 ms with each interval occurring on 25% of the
stop trials. The expected moment of response was based on the mean reaction time in the
previous block. The task started with three practice blocks to familiarize participants with
the paradigm. In the first block only go trials were presented (primary task). In the second
practice block, 25% of trials were stop trials, which only required inhibition of response.
In the last practice block, stop signals required both response inhibition and response
re-engagement. After practice, participants were administered four experimental blocks of
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64 trials each. Standardized instructions pressed participants not to wait for the stop
signal, but to continue pressing the buttons as quickly as they could.
The main dependent measure for this task is Stop Signal Reaction Time (SSRT). This
is an estimate of the time it takes before the inhibition process is engaged. SSRT cannot be
measured directly, but it can be estimated using the Race Model (Logan, 1994). According
to the Race Model response inhibition depends on the outcomes of a race between two sets
of processes that operate independently. One set starts with the onset of the go-stimulus
(the airplane at the left or right side of the screen) and results in the activation and execu-
tion of the response, whereas the other set starts with the onset of the stop signal and
results in ihe onset of the inhibitory process (Logan & Cowan, 1984). The response is
made or withheld, depending on which set of processes wins the race. In practice, SSRT is
calculated as follows: first, reaction times on go-trials are rank ordered on a time axis.
Then, the nih reaction time is picked, whereby n is defined by the product of the number
of reaction times in the distribution and the probability of responding given a stop signal.
This gives an estimate for the time at which the inhibition process runs to completion,
relative to the onset of the primary task stimulus. Third, the delay between on.set of the
primary task stimulus and the stop signal is subtracted from the /ith reaction time and thus
SSRT is estimated. For more detailed information on the calculation of SSRT. the reader is
referred to Logan et al. (1984). In addition to SSRT, other dependent variables included in
the analyses were; 1) the mean reaction time on go-trials of the primary task (measuring
latency of response execution). 2) the standard deviation of the reaction times on go-trials
of the primary task (measuring variability in the latency of the response execution pro-
cess), 3) the mean reaction time on the Change Response of the task (an indication of the
speed of the response re-engagement process), and 4) the standard deviation of the Change
Response latencie.s (to measure variability in the speed of the response re-engagement
process). Another measure often reported in research using the SST is the slope of inhibi-
tion function. Recently however. Band. Van der Molen. and Logan (2{X)3) indicated that
this variable is not a reliable indicator of differences in inhibition. Therefore, this variable
was not analyzed in the current study.
Procedure
Participants entered a double blind, placebo controlled, cross over trial of Mph. The
design of this trial and clinical outcomes are described in detail elsewhere (see Kooij et al.,
2004). We designed the trial hased on the medication study by Spencer et al. (1995). There
were two 3-week treatment periods for each participant, one period of 3 weeks for Mph
and one period of 3 weeks for placebo, with 1 week of washout in between.
The order of treatment (Mph-placebo or placebo-Mph) was randomized. Weekly
supplies of Mph (10 mg per tablet) or placebo were prepared and dispensed by the hospital
pharmacy in identically appearing tablets. Placebo tablets contained only a base granulate.
Mph tablets contained only Mph granulate. Medication was prescribed in four times or
five times a day dosing, depending on whether rebound occurred. Study medication was
titrated up from tow to high doses, to avoid exposure to high initial doses of active medi-
cation and to minimize side effects. Participants started with 0.5 mg / kg per day in week
I, followed by 0.75 mg / kg per day in week 2, and up to 1.0 mg / kg per day in week 3,
unless adverse effects emerged. A dose of 1.0 mg / kg has been shown to be a reasonable
upper limit dosage for clinical purposes (Sachdev & Trollor, 2000). To control for possi-
ble substance use during the trial, patients were asked unannounced twice to hand over a
urine sample.
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Repeated administrations of the inhibition tasks described above were obtained in week
3 (highest dose of Mph. or placebo) and in week 7 (highest dose ol" Mph, or placebo). Test-
ing started one hour and fifteen minutes after tablet intake. Mph peak concentrations in the
brain are reached after approximately 6(1 minutes (Volkow et at.. 1995). Maximal therapeu-
tic effects are reached within approximately 2 hours after ingestion (Swanson. McBumett,
Christian, & Wigal, 1995; Wilens, Biederman, Spencer, & Prince, 1995). The behavioral
half-life of the drug is approximately 3 hours (Solanto & Conners, 1982), Administration of
the inhibition battery took approximately I hour, so testing was completed between the
moment of peak Mph levels in the brain and the behavioral half-life value.
Besides two treatment orders {Mph-piacebo or placebo-Mph). inhibition tasks were
also administered in two different test orders (CPT-ChT or ChT-CPT), to be able to con-
trol for possible effects of fatigue and for effeets of declining medication efficacy.
Statistical Approach
In order to check whether treatment order or test order interacted with the effect of treatment
condition, separate MANOVAs were conducted for the dependent variables of the CPT and
the ChT, with treatment condition {Mph or placebo) as within subject factor and treatment
order (Mph-plac or plac-Mph) and test order (CPT-ChT or ChT-CPT) as between subjects
factors. If no overall interactions between treatment condition and treatment order or test
order were found, the effects of medication on the dependent viu"iables were further ana-
lyzed with ANOVAs with treatment condition as within subject factor. If, however, overall
interactions between treatinent condition and treatment order or test order were significant,
univariate cross-over results were interpreted only for those variables that did not show an
interaction. For variables that did show a univariate interaction, only data from the parallel
trial (the first three weeks of treatment) were analyzed in an ANOVA with treatment condi-
tion as between subjects factor. We adjusted our alpha level to .0125 (.05 divided by the
number of prtKcsses tested) to compensate for the number of comparisons made.
The data of one participant were excluded from the analyses for the ChT, because
mean scores on several dependent variables deviated more than 1.5 times the interquartile
range from the 25th or 75th percentile.
Results
Group characteristics for the two treatment order groups are shown in Table 2. Statistical
analyses confirmed that there were no differences between the two groups in number of
Table 2
Characteristics of Two Treatment Order Groups and of Total Group
Mph - Plac Plac - Mph Total group
(H = 24) (n= 19) (A^  = 43)
Men/Women 14/10 8/11 22/21
AgelM.SD) 38.5(9.9) 38.3(10,6) 38.4(10.1)
IQ{M,SD) 100.3(17.6) 100.2(18.7) 100.3(17.9)
Dose (mg) (M, S£)) 74.8(15.6) 65.3(16.9) 70.6(16.7)
Dose (mg / kg) (M. SD) .97 (.13) ,88 (.23) .93 (.18)
Note. Mph = methylphenidate; Plac = placebo.
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participants, gender distribution, age, IQ, absolute dose (in mg / day), or relative dose (in
mg / kg / day) of Mph at time of testing.
Main Analyses
Continuous Performance Test. There was no interaction between treatment condition and
treatment order (Wilks' A = .77, F(5, 35) = 2.12, p = .086), nor between treatment condi-
tion and test order (Wilks' A = .93. F(5, 35) = .49, p = .779). Therefore, the effects of
treatment condition on the dependent variables of the CPT were further analyzed without
taking either treatment order or test order into account. A MANOVA with treatment con-
dition as within subject factor showed an overall significant effect of treatment (Wilks' A
= .60, F(5, 38) = 4.98, p = .001, TI^  = .40). Separate ANOVAs with treatment condition as
within subject factor (see Table 3 for means and standard deviations) revealed a signifi-
cant decrease of commission errors with Mph (F(l, 42) = 10.88,/J = .002). The accompa-
nying effect size (Tj^  = .21) was large (Cohen, 1988). The increase in mean reaction time
with medication (F(l, 42) = 5.10, p = .029) was not significant. The accompanying effect
size, however, was medium (Tl" = . 11). Standard error of hits significantly decreased with
Mph (F(l, 42) = 7.15,/>= .011), with a large effect size (T)^  = .15). There was a significant
improvement in attentiveness (d') (F(l, 42) = 8.17,/J = .007). The effect size of the latter
increase was large (T|' = .16). Risk taking (|3) did not show a change with medication
,42) = .43, p ^ .837, r\' = .00).
CPT - Analyses of IS!. For several variables (commission errors, mean hit reaction time,
and standard error of reaction time) of the CPT, separate data are available for the three
different ISls. These variables were analyzed in ANOV As with two within subject
factors: ISI (three levels: 1, 2, or4t>) and treatment condition with two levels, to check if
Mph has a different effect for different ISIs. Because of possible violations of the sphe-
ricity assumption, degrees of freedom and related /; values were corrected according to
the Greenhouse-Geisser method. For commission errors, there wa.s no significant interac-
tion between treatment condition and ISI (F(l.89, 79.2!) = .54, p = .940. r\~ = .00). Mph
did not change the number of commission errors made over the different ISIs. As can be
seen in Figure I, there was a significant interaction effect of ISI and treatment condition
for mean hit reaction time (F(1.75, 73.53) = 5.15. /? = .011, V = .11). Post hoc paired
samples /-tests revealed that the difference between placebo and Mph was significant
only for an ISI of 1 s (/(42) = 3.95, p = .000). The accompanying effect size was medium
(Cohen's d = .60). Mph significantly slowed down the mean hit reaction time for an
ISI of Is.
Table 3
Descriptives and Statistics for Continuous Performance Test Variables
Variable
Mean hit reaction Time
(M, SD)
Standard error (A/, SD)
Commissions (M. SD)
Attentiveness (d') (M, SD)
Risk taking (p) (A/, SD)
Placebo
333.5 (48.7)
6.0 (3.3)
13.6(7.6)
3.1 (0.9)
.06 (.05)
Mph
342.6 (48.7)
4.9 (2.4)
10.7(7.2)
3.4 (0.9)
.07 (.06)
F
5.10
7.15
10.88
8.17
.43
/'
.029
.011
.002
.007
.837
.11
.15
.21
.16
.00
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ISI 2 ISI 4
Fiaure I. Mean Hit ReacUon Time (HRT) (in ms) on CPT as a Measure of ISI and Treatment
Condition.
Figure 2 displays Ihe standard error of mean hit reaction time. For this variable we
established a significanl interaction of ISI and treatment condition (f(1.88. 79.06) =
5.07. /* = .010, T]' = .11). Post hoc paired samples /-tests showed the eflecl of Mph to he
significant only for an ISI of 4 s (/(42) = -3.14, /) = .003). The matching effect size was
close to medium (Cohen's d = .48). So Mph lead to less variability in responding at a
large ISI.
Cfiange Task. There was no significant interaction between medication treatment condi-
tion and test order (Wilks' A = .91, F(5. 34) = .67, p = .628). Therefore, the effects of
medication for this tes( v^ e^re further analyzed without taking test order into account. There
was, however, a significant interaction between treatnieni condition and treatment order
(Wilks' A = .51, F(5, 34) = 6.60,/? = .000). Univariate tests revealed significanl interactions of
treatment condition and ireatmcnl order for mean reaction time (/-(I, 38) = 12.20,p = .(X)l),
and standard deviation of reaction times (F( 1, 38) = 21 .(K), p = .000). Apparently, for the.se
variables il made a difference whether Mph or placebo was administered first. For these
variables, main effects of treatment condition were therefore analyzed only for the parallel
trial (after three weeks of treatment, during the highest dose of Mph or placebo).
a:
X
lU
17.5
17 H
16.5
16 i
15.5
15
14.5
ISM ISI 2 tsu
Figure 2. Standard Error of Hit Reaction Time (SE HRT) (in ms) on CPT as a Measure of ISI and
Treatment Condition.
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The variables that did not show univariate interactions of treatment order and treat-
ment condition were further analyzed with ANOVAs with ireatment condition as within
subject factor (see Table 4 for means and standard deviations). For SSRT. no decrease
with medication was found ( F ( l , 4 ! ) = 3.08,/; = .087, Ti" = .07). Inhibition as measured by
this variable did not improve with Mph. We did not establish a decrease in mean reaction
time on the Change Response with Mph (F( l . 41) = 4.84, p = .033). Tbe accompanying
effect size, however, was medium (ri" = .11). The standard deviation of these Change
Response reaction times was not different under medication or placebo (F( I, 41) = .26.
For tbe two variables that showed significant interactions between treatment order
and treatment condition, data for the first point of measurement (after three weeks) were
compared in an ANOVA witb treatment condition as a between subjects factor (.see Table 4
for means and standard deviations). Tbere was no significant effect of Mpb on mean reac-
tion time (HI. 40) = .91, /j = .346, rj- = .02) nor on the standard deviation of reaction
times (/•( 1.40) = 4.02. p = .052, n ' = -09).
Post-hoc Analyses
Several exploratory analyses were conducted to characterize tbe results more completely.
Because of tbe exploratory nature of tbese analyses, alpha level was set at .05.
In order for a medication effect to be not only statistically but also clinically signifi-
cant, one would like medication to normalize scores tin dependent variables. Ideally, one
would compare ihe scores of participants with those of a normal control group or witb a
norm group. However, 82% of tbe norm group for tbe CPT used in our study was in the
age range of 18-30. This is mucb younger than our ADHD group. Therefore we decided
to compare the mean of our medicated ADHD group with tbe group mean of a normai
control sample from another .study for tbe variable that showed tbe largest effect size in
our study: commission errors on the CPT. Tbe normal control participants (mean age 33.4
years, 5lWr males) in a study by Epstein et al. (2001) carried out the exact same version of
the CPT a.s our ADHD participants. A one sample r-test showed no differences (/(42) = 1.65.
p= .\\) between the mean number of commission errors of our medicated ADHD sample
(A/ = 10.7) and the mean of tbe normal control sample (n = 30. Xf = S.9), indicating a
similar level of inhibition in both groups. When we compared our ADHD sample off medi-
cation (placebo scores) and the same normal control group, the difference was significant
Tahle 4
and Statistics for Change Task Variables
Variable
SSRT (M. SD)
MKT[M.SD)'
SD RT (M. SD)'
Change Response
Change Response
MRJ (M.SD)
SDRTiM.SD)
Placebo
220.0(56.4)
434.1(82.7)
96.9(32.3)
475.3(89.7)
117.0(43.4)
202
407
78
457
113
Mpb
.3 (50.5)
.4 (95.9)
.2 (28.4)
.1(71.1)
.2 (43.8)
3
4
4
/-
.08
.91
.02
.84
.26
/'
,087
.346
.052
.033
.615
.07
.02
.09
.11
.01
Nnii: .SSRT = Slop Sitjiiiil Rcaciion Time; MR T = mean reaction time; SD = standard deviation;
RT = reaciitm lime.
'Placebo: n - 19; Methylphenidate: n = 2.1 (parallel trial analysis only).
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(/(42) = 4.04, p =.(X)): the ADHD group showed worse inhibition capacities than the
normal control group from Epstein et al.
It is possible thai mcdicaiion effects are found only when there is nK)m for improve-
ment. To check this possibility, we compared medication effects (difference scores
between placebo and Mph) on CPT commissions and on ChT SSRT for participants with
placebo scores below and above the means of these variables. For CPT commissions, the
group {/I = 18) who luaiic a larger number of commission errors (compared to the mean
placebo commission score) improved significantly more wilh Mph than the group who
made a smaller number of errors (H = 25; again compared to the mean placebo score) (F(l,
4!) = 8.21. p = .007. X]- = .17). For SSRT on the ChT, the effect of high versus low
placebo scores was even larger. Participants who showed slower than average SSRTs on
placebo (n = 22) improved much more with medication than participants who responded
faster than average to begin with (/i = 20) (f(l , 40) = 25.15, p= .000, r|" = -^ y) This latter
result Is in contrast with the nonsignificant results in the total sample. Apparently, Mph
does significantly improve inhibition as measured by the ChT in participants who show
low scores on SSRT to begin with.
To check what the predictive value of improvement on cognitive tests is for clinical
respondership, we conducted a discriminant analysis to detennine whether the difference
between placebo and medication scores for the two most often reported dependent variables
for our neuropsychologieal tests (commission errors and SSRT) eould predict clinical
respondership. Clinical respondership for each participant was determined according U) Kooij
et al. {2(X)4), who defined clinical response as a decrease of at least two points on the investi-
gator ba.sed Clinical Global Impression Scale for ADHD over the total treatment period (three
weeks), and a 30*?^  or more symptom reduction on the self-reported ADHD Rating Scale. The
ovemll Wilks' lambda was significant for chajige in cotiimission errors on the CPT (A = .79.
X-(2, W = 43) = 9.15,/) = .010). but not for the SSRT of ihe ChT. Only the significant discrim-
inant function was interprcted. Clinical respondership could be correctly cla.ssified based on
decrease of commission errors in 197c of the cases. Ten of 16 respondent were correctly clas-
sified, leading to a sensitivity of 63%. Twenty-three of 26 non-responders were correctly
classified as such, indicating a s[Tecificity of 89*^. Positive predictive power of the decrease
in commission errors on clinical respondership was IH^/i. negative predictive power was
79%. In order to take into account chance agreement, we computed a kappa ctxrfficient and
obtained a value of .53, which can be considered moderate (Landis& Koch. 1977).
Finally, we perfonned a partial correlation analysis to check whether the amount of
commission errors on (he CPT during Mph was related to several clinical variables rather
than to Mph. when placebo-commission errors were purtialed out. There were no signifi-
cant correlations between Mph-commission errors and any of the following variables:
severity of ADHD (number of DSM-IV symptoms; / = -.I4./J = .37), relative Mph dose at
endpoint {in mg / kg; r = -.03, /J = .86). absolute dose at endpoint (mg; r = -.00, p = .99),
CO morbid anxiety disorder (r=.27,/7= .09). number of co morbid disorders (r= .28,/? = .07),
or lQ(r=.06,p=.71) .
Discussion
The pre.sent study was designed to examine the effects of Mph on inhibition and other
cognitive measures in a sample of adults wilh ADHD. The analyses indicated rather strong
effects of Mph on inhibition and response measures on the CPT. However, no medication
effects on inhibition and otlicr response tneasures were found on the ChT.
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With respect to the CPT. the inhibition resull.s confirm our hypothesis and they are in
line with previous research in ADHD ebildrcn (Losier et al., 1996). Fur adults, very few
medication studies of commission errors on tbe CPTare available. Results by Gualtieri et al.
(1985) indicate a decrease in commission errors on a CPT. although this decrL'a.se just fell
short of significance. However, our study provides more reliable changes, since Gualtieri and
colleagues tested after a single dose of Mph. rather than an entire week of medication.
Wben breaking down commission errors into number of errors lor different ISIs, the
results indicate that the commission errors occur independently of event rate, both in the
placebo and the Mph condition. This result may underline the suggestion tbat inhibition is
not influenced by a behavioral activation level (Sergeant, Oosterlaan, & Van der Meere.
1999). Wben we eompared participants wbo made many commission errors in the placebo
condition witb tbe participants who made few errors in tbe placebo condition, tbe effect of
medication was significantly larger in tbe group wbo perlormed worse to begin witb. So the
effect of Mpb on inhibition is larger in a subgroup tbat shows more room for improvement.
We bypolbesizcd the effect of Mpb on SSRT of tbe CbT to be stronger tban what we
actually found. Our finding cannot be compared with adult ADHD data, since the effect of
Mpb on SSRT of the ChT bas not been studied in tbis population before. In cbildren with
ADHD, three .studies reported substantial faster SSRTs with Mph (Scberes et al., 2(X)3;
Tannock et al., 1989. 1995). while Overtoom and colleagues (2003) did not observe
changes in SSRT with Mph. Post hoc analyses of our data indicated that Mpb does induce
a large improvement in SSRT for a subgroup of our participants whose SSRT on placebo
was slower (indicating worse inhibition) tbat tbe mean placebo SSRT score of the entire
group. However, this does not explain wby we did not fmd an improvement of SSRT in
the entire ADHD group, whereas we did find a decrease of commission errt>rs on ibe CPT.
Possible explanations for tbis deviance will be explored later in this discussion.
Other cognitive prtxresses measured by tbe two paradigms used in tbis study include
latency and variability of respt>nse execution prtKesses (mean reaction time and variability in
reaction times on both CPT and ChT), attentiveness (d'; CPT), response style (P; CPT) and
respt>nse nc-cngagement (MRTand SD; only in the ChT). Reaction limes did not cbange with
medication on the CPT. This is in contrast with research in cbildren (Klorman, Brtimaghim,
Fitzpatrick. & Borgstedt. 1991; Riccio et al., 2(H)1) and adults with ADHD (Riordan et al..
1999), in whicb faster MRTs with medication bave been established. Since tbe accompany-
ing effecl size of this result was medium, we decided to look into effects for different ISIs.
Here, we found tbe expected slowing of MRT witb longer ISIs (ADHD subjects have been
shown before to show slower RTs with longer ISIs, see Scberes et al., 2(X)I). Only with tbe
shortest ISI, however, did medication slow RT significantly. Tbe overall slowing of MRT
with medication seems to be best and solely explained by a slower MRT with the shortest ISI.
Apparently, Mph allows ADHD participants to respt)nd less impulsively at short ISIs. This is
in accordance wilh research by Berman et al. (1999), which showed tbat Mph slowed down
RT only on tbe most difficult, high load test conditions (the shortest ISI can be considered to
be a high load). Tbis result implies that Mpb may improve self-regulatory abilities, as sug-
gested by Douglas (1988, 1999). In view of the non-significance of tbe MRT result, tbis state-
ment is tentative, but worthy of further consideration, given the medium effect size.
We also found tbat treatment with Mpb decreased variability of mean reaction times
on ihe CPT- On tbe CbT, this change was not significant, although the accompanying
medium effect size implies that this may have been a power issue. This improvement in
variability is in agreement with earlier studies in children with ADHD (Tannock et al.,
1989, 1995). No comparable research is available for adults wilh ADHD. The overall
decrease of variability in reaction times on the CPT could be broken down into different
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effects for different ISIs. Mph effects on variability seem to be larger for longer ISIs. This
is propitious, since ADHD is known to lead to increasing variability in response execution
wiih slow event rates (i.e., longer ISIs) (Scheres et ul.. 2001; Van der Mcere, Shalev.
Borger. & Gross-Tsur, 1995). Apparently Mph increased ihc behavioral activation level
(Sanders. 1998), which allowed participants to respond more evenly.
Response re-engagcment on the ChT (the Change Response) was not sped up signifi-
cantly by Mph. This is in contrast with a recent study, showing thai Mph enhanced task
switching performance in ADHD children (Kramer. Cepeda. and Cepeda. 2(X)1). and with
earlier findings on ihe effect of Mph on the Change Response (see the Materials section
for an explanation of the Change Response) in children with ADHD (TanntKk, 199.S). No
data on the effect of Mph aduli pcrforinance on this variable are available. Again. looking
at Ihc accompanying etfecl size for this result (ri-=; .11), this result may be worth considering
further in a larger sample. Variability in response rc-cngagement reaction times was not
affected by medication. No previous studies have reported on this measure in adults with
ADHD, but based on decreased response variability in primary reaction times with Mph,
one might expect this variability on a secondary task to decrease as well. Tbis was indeed
found in a child ADHD sample (Tannock, 1995). Possible explanations for this diver-
gence will be explored later on in the discussion.
Attentiveness (d') on the CPT increased with medication, which is in keeping with
medication studies in children with ADHD (Losier, 1996), and with studies in adults with
ADHD (Kupcrman et al.. 2001). Risk taking (p) did not change with Mph treatment,
which also is in line with previous studies in children (Losier. 1996). In adulls with
ADHD, the effect of Mph on this variable has not been reported before. It should be
mentioned, however, that the standard deviation of this parameter was about as large as
Ihe mean, which makes interpreting any results with this variable difficult. It also raises
questions about the accuracy of the calculation of this measure by tbe scoring program.
Similar observations were made by Epstein et al. (1998).
Exploratory analyses indicated that Mph may indeed normalize the number of
commission errors made on the CPT by ADHD participants to the level of a normal con-
trol group. We only compared data for one dependent variable, so we cannot generalize
this result to other cognitive abilities, but il is a promising result for clinical practice.
Future research should compare other processes, preferably with a normal control group
recruited especially for that study, since the normal control sample in the study by
Epstein et al. (2001) was slightly younger than our ADHD sample. If other variables of
the CPT also normalize with Mph, this may render this test suitable for quantitalively
establisbing the effect of Mpb on an individual level. This would be a valuable contribu-
tion to the entire ADHD population (both children and adults), since changes in symp-
toms are now indicated by eitber observers, who may not always be as objective as
necessary, or by patients themselves, who may not have an accurate perception of these
changes (Barkley, Fisher. Smallish. & Fletcher, 2(H)2). The clinical value of a decrease in
commission errors is also substantiated by the receiver operating cbaracteristic analyses
we performed. We ascertained Ihat the overall predictive value of Ihe difference between
placebo and medication commission errors on Ihe CPT was 79%. The related sensitivity
of 63% indicates that the decrease in commission errors from placebo to Mpb has a mod-
erate predictive value for clinical respondership. The specificity of this decrease seems lo
be better: 88% of participants who did not show a large decrease, were not clinical
responders. Elwood (1993) argues that a more accurate measure of utility of neuropsy-
chological variables is the positive and negative predictive power. Positive predictive
power for the cbange in commission errors indicates that of those participants who
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showed large decreases in this type of errors, 78% were responders. Conversely. 79% of
participants who showed a smaller decrease of commission enors were correctly classi-
fied as non-responders.
We found no significani correlations between medication commission errors on tbe
CPT and several clinical variables, while partialing out placebo commission errors. This
indicates thai improvement in commission errors with medication is not influenced to a
significant extent by ihe severity of ADHD, tbe administered dose of Mpb (either relative
or absolute), the number of comorbid disorders, comorbid anxiety disorder, and IQ. Of
course these analyses are only superficial, and no defmitive conclusions can be drawn
based upon tbese result.s. Larger groups of participants would allow for more substantial
analyses into these issues. However, tbe results do suggest that the effect of Mpb on com-
mission errors on the CPT takes place rather independently of the variables mentioned.
For all the exploratory analyses, it should be stressed Ihal only a few variables were used
in the analyses. So exploratory results only play up to future research; of course other vari-
ables and otber tests should be evaluated belore firm conclusions can be drawn.
All in all. many of the effects found in our study are in accordance wilh previous Mpb
studies witb either adults with ADHD and / or children witb ADHD. However, two deviant
results were established. The first deviant result is lack of reduced variability in the reac-
tion times on the Change Response. This may be due to large within group variability for
this variable. Tbe decrease in mean reaction time of tbe Cbange Response is close to
significance, while ihe decrease in the standard deviation of reaction times is not. Propor-
tionally, however, tbese decreases are similar for both variables. Tbe witbin group vari-
ance is. again proportionally seen, much larger for the standard deviation of mean reaction
times on tbe Change Response than for tbe mean reaction lime of tbe Cbange Response,
which could easily lead tt) lack of significani ANOVA results.
The second and main divergent result is a lack of robust decreases in SSRT on the
ChT for the toial ADHD group. Several explanations can be given for tbis deviation.
A possible explanation can be found in Ibe work of Tannock and colleagues (1995), who
found an inverse U-sbaped dose-response curve for SSRT in a ChT: Mph induced the
largest reduclion in SSRT wilh a medium dose (0.6 mg / kg). Decreases in SSRT were nol
established witb low (0..1 mg / kg) nor with higb (0.9 mg / kg) do.ses. In our sludy. the
mean relative dose (0.9 mg / kg) was similar to the high dose in Tannock's study. Future
research with different doses of Mph sbould prove wbetber medium doses improve inhibi-
tion on tbe ChT in adults with ADHD.
Another elucidation for our absence of a robust reduction in SSRT may be offered by
Scberes et al. (2()()3), who indicated Ibat a Stop Task with a tracking mechanism may be
more sensitive to medication effects tban tbe version with a fixed intervals method, used
here. The version with a tracking mechanism assures a constant inhibition probability of
50%, which provides the mosl reliable estimation of SSRT (Band et al.. 2003). When tbe
percentage inhibition is lower or higher than 5O'5i. estimations of SSRT may be under-
estimated or overestimated, respectively. The results of a recent study (Aron. Dowson.
Sahakian, & Robbins. 2003) indicate that Mpb may indeed itiiprove inhibition as
measured with a tracking version of tbe SST in adults witb ADHD. Our data evoke ibe
important question of wby Mph bas a robust effect on commission errors on ibe CPT. and
not on SSRT on the ChT. wbile botb variables are supposed to measure inbibition. It may
be the ca.se that tbe two operationalizations of response inhibition actually tap into slightly
different abilities. This suggestion is underpinned by ihe low correlation between SSRT
and commission errors (r = .21). The nature of the two tasks also indicates several differ-
ences. First of ail. in tbe CPT, the signal to withhold a response is given before tbe actual
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response is slarted up, while the ChT requires withholding a response that has already
commeneed in a kirge pan o\' the trials. Secondly, there is a dilTercnce in the percentage of
targets in bolh tasks. In the ChT. 25% of trials require withholding a response, while this is
oniy called for in \QVc of the trials in the CPT. This discrepancy may cause differences
in the state of arousal that participants are in while pertbmiing bolh tasks, which may
influence the effect of Mph on hoih tasks.
A third difference between the two tasks is the nature of the stop signal. In the CPT.
this signal is visual, and similar to the target signals. In the ChT. the stop signal is audi-
tory. It has been suggested that children with ADHD have particular difficulties with
processing information in the auditory modality (Riccio. Hynd. Cohen. Hall. & Molt.
1994). If this is also the case in adult ADHD, this factor may interfere with improvement
on the ChT with medication. Besides this difference in nature of the stop .signal, the
mere fact that processing of the stop signal requires a different modality than processing
of the stimulus iiself may cause a difference in medication effect in comparison with the
CPT.
Yet another important difference can be found in the level of difficulty of both tasks.
Inhibition on the ChT requires withholding a response while being in a more or less
alerted state. The participant is anticipating a plane on either side of the screen and has to
actually pay continuous attention in order to give the correct response in this two-choice
reaction time ta.sk. With the CPT, it seems easier to drift into a semi-alert state of attention.
since this i.s a simple go- no go task. Every stimulus requires the same response, that is,
pressing the space bar. Besides this difference in difUculty. the ChT requires response
re-engagement utter inhibition of the primary response. This also makes the inhibition
process in this task a different, and more difilcult process from inhibition in the CPT.
Tannock et al. (1995) have indeed found smaller Mph effects on SSRT in the more
demanding ChT. compared to the easier SST (used in their 1989 study). Increased cogni-
tive load may reduce the magnitude of the effect of stimulants. This is in line with previ-
ous research, where performance decrements at high doses have been found on tasks that
were complex, or on the most difficult level of tasks (Bennan et al., 1999; Douglas. 1988;
Tannock & Schachar. 1992). This underscores the importance of studying the effects of
different doses in adults with ADHD, since the optimal dose for ameliorating behavioral
symptoms, may not necessarily the most effective dose for several cognitive abilities
(Cantwell & Swanson. 1997).
We tried to establish the effect of Mph on inhibition in adults with ADHD. Although
our data suggest positive effects of the drug on inhibition, we did not test whether this
holds for all forms of inhibition. As noted by Hvenden (1999), "there is not one unitary
impulsivity or only one type of impulsive behavior" (p. 348). Different researchers have
proposed different taxonomies for subdividing inhibition (Barkley. 1997: Nigg. 2{KM). So
further studies are necessary to determine which form of inhihition is improved by Mph
and to better operationalize different forms of inhibition.
In sum, current findings showed that, in adults with ADHD, Mph has large beneficial
effects on inhihition as measured by the CPT. It also has a large effect on inhihition as
measured by the ChT, but only in those subjects who show slow inhibition times off-
medication. In addition to improving inhibititjn. Mph decreases variability in response
execution processes on the CPT. and it improves the ability to distinguish signal from
noise on the CPT. Thus. Mph does not only effectively ameliorate clinical symptoms in an
adult ADHD population, as shown by several researchers (for reviews, see Wilens et al.,
2(K)2 and Faraone et al., 2()()4), but its positive effects can also be demonstrated on several
cognitive processes important in daily life.
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